Evotec and Boehringer Ingelheim achieve second milestone

Evotec and Boehringer Ingelheim have achieved the second milestone in their research collaboration. Under the terms of the drug discovery contract, Evotec will receive a milestone payment from Boehringer Ingelheim, which was granted for the identification of a number of lead series for a priority receptor target.

This is the second time within 18 months that a target moves into lead optimisation.

Further projects within the multi-target collaboration are said to be progressing on schedule and are on track to achieve additional project milestones for which Evotec is entitled to additional payments from Boehringer Ingelheim.

"We are very pleased with the rapid progress achieved in the collaboration. We are looking forward to further progress with the two advanced projects and to further exciting research activities," said Professor Mikael Dolsten, head of corporate division pharma research/discovery, Boehringer Ingelheim.